Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer

Fig. 4

SLC6A1 overexpression promotes the resistance to docetaxel of prostate cancer cells. a Cell proliferation of PC3 and LNCaP cells treated with docetaxel in different concentrations. The IC50 concentration of PC3 cells was 33.89 nM, and the IC50 concentration of LNCaP cells was 3.40 nM. b Cell proliferation of PC3 and LNCaP cells transfected with SLC6A1 expression vector or the specific shRNA, and also treated with docetaxel in its IC50 concentration. c After treatment with docetaxel at IC50 concentration, the cell number and morphological changes of different PC3 cells were observed under microscope(X10). d Volume changes of PC3 transplanted tumor in SLC6A1 overexpression group and control groups after docetaxel treatment. e Effect of Docetaxel on ROS in PCa cell lines

Back to article page
\